Deans ZCReview of the implementation of plasma ctDNA testing on behalf of IQN Path ASBL: a perspective from an EQA providers’ survey.
Dihydropyrimidine dehydrogenase pharmaco- genetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patients. British Journal of Cancer
A Ruzzo1,23, F Graziano2,23, Fabio Galli3, Francesca Galli3, E Rulli3, S Lonardi4, M Ronzoni5, B Massidda6, V Zagonel4, N Pella7, C Mucciarini8, R Labianca9, M T Ionta6, I Bagaloni1, E Veltri10, P Sozzi11, S Barni12, V Ricci5, L Foltran13, M Nicolini14, E Biondi15, A Bramati16, D Turci17, S Lazzarelli18, C Verusio19, F Bergamo4, A Sobrero20, […]
Acid-free glyoxal as a substitute of formalin for structural and molecular preservation in tissue samples. Plos One
Gianni Bussolati1, Laura Annaratone1, Enrico Berrino2, Umberto Miglio2, Mara Panero2, Marco Cupo1, Patrizia Gugliotta1, Tiziana Venesio2, Anna Sapino1,2, Caterina Marchiò1,3 1Department of Medical Sciences, University of Turin, Turin, Italy 2Candiolo Cancer Institute – Fondazione del Piemonte per l’Oncologia (FPO), IRCCS, Candiolo, Italy 3Pathology Division, Azienda Ospedaliera Universitaria Città della Salute e della Scienza di Torino, […]
Marco LucarelliA New Targeted CFTR Mutation Panel Based on Next-Generation Sequencing Technology. The Journal of Molecular Diagnostics
BRAF p.V600E-specific immunohistochemical assessment in colorectal cancer endoscopy biopsies is consistent with the mutational profiling. Histopathology
Outcome evaluation of patients with newly diagnosed anaplastic gliomas treated in a single institution. Future Medicine
5 most important considerations when testing a new drug